Huntington's Disease: Diagnosis & Clinical Symptoms
Huntington's disease (HD) is the most common inherited cause of chorea in adults. It is a complex autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4, resulting in toxic mutant huntingtin protein that destroys GABAergic medium spiny neurons of the basal ganglia. HD manifests as a triad of involuntary movements, cognitive decline, and neuropsychiatric symptoms, with a mean onset of 30–50 years and relentless progression over 15–20 years. US prevalence is approximately 5 per 100,000, with higher rates in White populations and founder effects in isolated communities (e.g., Lake Maracaibo, Venezuela). The 2022 HD Integrated Staging System (HD-ISS) has redefined the disease by pathologic rather than clinical markers, enabling earlier diagnosis and research in presymptomatic stages.
Bottom Line
- Genetics: Autosomal dominant; CAG repeats on chromosome 4 — <26 normal, 27–35 intermediate (risk of anticipation in offspring), 36–39 reduced penetrance, ≥40 full penetrance, ≥60 juvenile onset
- Clinical triad: Chorea + cognitive decline (subcortical dementia, frontal executive dysfunction) + neuropsychiatric symptoms (depression, irritability, psychosis, suicidal ideation in up to 30%)
- Diagnostic hallmarks: Forehead chorea (helps distinguish from tardive dyskinesia), motor impersistence (tongue protrusion, milkmaid's grip), caudate atrophy with "boxcar ventricles" on CT/MRI
- Genetic testing: Follow the HDSA testing protocol; pretest counseling essential given suicide risk after predictive testing; minor children should not undergo testing unless symptomatic
- Key phenocopies: C9orf72 disease (most common phenocopy in White populations), SCA17 (HDL4), DRPLA, HDL2 (sub-Saharan African descent)
- HD-ISS: Stage 0 (gene-positive), Stage 1 (biomarker changes), Stage 2 (prodromal), Stage 3 (clinical disease) — enables presymptomatic trial enrollment
Identifying Chorea
The term chorea (from Greek choreia, meaning dance) describes involuntary movements that are random, purposeless, and unpredictable — brief and abrupt, flowing freely from one body part to another. Chorea can be partially suppressible and can involve any part of the body with widely varying amplitude and frequency. Key associated examination findings include:
- Motor impersistence: Inability to sustain posture; best demonstrated by sustained tongue protrusion (ask for 10 seconds without biting — patient repeatedly draws tongue back) and handgrip ("milkmaid's grip" — fluctuating grip intensity)
- Parakinesia: Blending chorea into purposeful movements (e.g., choreiform arm movement masked by adjusting eyeglasses)
- Anosognosia: Patients may be unaware of movements, making caregiver input essential
- Ballism: Most severe form — high-amplitude, flinging proximal limb movements (sometimes considered a distinct entity)
Examination Tips
Patients should be examined without shoes and socks and with legs/feet suspended to detect subtle chorea. In mild cases, movements may appear as restlessness or fidgeting. Look for "hung up" or pendular reflexes. Distinguish chorea from dystonia (slower, sustained, with null point), myoclonus (fast jerk without flowing quality), and tics (premonitory urge).
Diagnostic Approach to Chorea
By Body Distribution
| Distribution | Key Associations | Clinical Pearls |
|---|---|---|
| Orobuccolingual | Tardive dyskinesia (most common), chorea-acanthocytosis (feeding dystonia), McLeod syndrome, neuroferritinopathy, NMDA receptor encephalitis, Lesch-Nyhan, acquired hepatocerebral degeneration | Always review current and recent medication exposure for DRBAs |
| Forehead | Huntington disease | Not pathognomonic but helps distinguish HD from tardive syndromes; subtle frontalis/eyebrow movements easily missed. TD can co-occur in HD patients on antipsychotics |
| Hemibody | With brain lesion: Vascular (contralateral STN/basal ganglia/thalamus), nonketotic hyperglycemia, infections, tuberous sclerosis Without lesion: Sydenham chorea, polycythemia vera |
Always check serum glucose in acute hemichorea — even without known diabetes. Hemichorea from hyperglycemia may persist weeks–months after glucose correction |
By Acuity of Onset
| Acuity | Likely Categories | Approach |
|---|---|---|
| Acute / subacute | Acquired: structural (stroke), drug-induced, infectious, autoimmune/paraneoplastic, metabolic/endocrine, hematologic | Urgent evaluation: CBC, CMP, TSH, ESR, ANA, anti-DNA, lupus anticoagulant, antiphospholipid antibodies, autoimmune encephalitis panel (if <1 year), brain MRI; pregnancy test if applicable |
| Subacute (unclear timeline) | Paraneoplastic, autoimmune (IgLON5, NMDA, LGI1) — "do-not-miss" diagnoses due to treatment responsiveness | Autoimmune encephalitis panel, paraneoplastic antibodies (anti-Hu, anti-Ma, P/Q VGCC, CRMP-5, CASPR2) |
| Chronic / progressive | Genetic: HD (≥1 year), phenocopies, other hereditary causes | Brain imaging (atrophy patterns, calcification, iron deposition) + targeted genetic testing; if non-diagnostic, consider whole exome/genome sequencing |
Huntington Disease: Genetics
| CAG Repeats | Classification | Clinical Manifestation | Risk to Offspring |
|---|---|---|---|
| <26 | Normal | No disease | ~0% |
| 27–35 | Intermediate range | Normal (rare symptomatic case reports) | Increasing risk of anticipation in offspring |
| 36–39 | Indeterminate range | Incomplete penetrance, typically later onset | Increasing risk of anticipation in offspring |
| ≥40 | Full penetrance | Complete disease penetrance; onset typically 30–50 years | 50% |
| ≥60 | Juvenile onset | Childhood/early adult onset; predominantly parkinsonism, dystonia, and seizures (Westphal variant) | 50% |
| ≥80 | Very early juvenile | Childhood onset; parkinsonism and seizures predominate | 50% |
Anticipation
Anticipation is the genetic phenomenon of offspring presenting at earlier age or with worsened symptoms compared to the parent. In HD, this occurs due to expansion of CAG repeats during gametogenesis, much more commonly during spermatogenesis. Consequences:
- Offspring of an affected father may develop HD much earlier in life
- Intermediate-range parents (27–35 repeats) may have children with fully penetrant disease
- Absence of family history can occur due to: misattributed parentage, misdiagnosis in prior generations, early death of the parent, or de novo expansion from intermediate alleles
HD Without Family History
A diagnosis of HD should be considered even without family history. People with HD can have absence of family history because of misattributed parentage, misdiagnosis in prior generations, or early death of family members. Additionally, intermediate-range alleles (27–35 repeats) can expand to pathogenic range in offspring through anticipation, particularly via paternal inheritance.
Genetic Modifiers of Age of Onset
CAG repeat length accounts for approximately 50–70% of the variance in age of onset. Other factors include:
- DNA mismatch repair genes: MSH3, MLH1, PMS1, PMS2, FAN1 — these drive somatic CAG repeat expansion in striatal neurons and are the most powerful genetic modifiers identified (GWAS by the GeM-HD Consortium)
- Somatic instability: CAG repeats continue to expand in postmitotic neurons, with the greatest expansion in the striatum (matching the selective vulnerability pattern)
- Environmental and lifestyle factors also modify onset, making precise prediction from CAG length alone unreliable
Clinical Presentation
Motor Symptoms
- Chorea: Most visible sign; can affect all body parts including muscles of speech, swallowing, and respiration. Initially subtle (restlessness, parakinesia), then gradually increases before stabilizing; in later stages, may be replaced by worsening parkinsonism and dystonia
- Forehead chorea: Subtle but characteristic; helps distinguish HD from TD in patients on antipsychotics
- Eye movement abnormalities: Slowed and delayed saccades, saccadic intrusion of smooth pursuit; with progression, patients require head movements/thrusts to initiate voluntary eye movements
- Gait: Wide-based, lurching stride with choreiform and dystonic components
- Other motor phenomena: Dystonia, myoclonus, ataxia, tics, motor impersistence
- Late stage: Chorea decreases while parkinsonism and dystonia worsen — pharmacotherapy must be adapted accordingly
Neuropsychiatric Symptoms
Frequently present years before motor onset and are often more disruptive than the movement disorder:
| Symptom | Key Points |
|---|---|
| Depression | Very common; may be the presenting symptom years before motor onset |
| Irritability / aggression | Common and disruptive; can lead to interpersonal conflicts and caregiver burnout |
| Anxiety | Prevalent; may be worsened by awareness of disease progression |
| Suicidal ideation | Prevalence up to 30%; suicide is the 3rd most common cause of death (6.6%) after pneumonia and infections. Mental health should be a focus of every visit |
| Impulsivity | Orbitofrontal disinhibition; impulsive purchases, risky behaviors. If firearms are in the home, safety must be addressed early |
| Psychosis | Less common but occurs; auditory hallucinations, paranoid ideation |
| Obsessive-compulsive behaviors | Repetitive behaviors, perseveration; overlap with frontal executive dysfunction |
| Apathy | Distinct from depression; loss of motivation and initiative. Antidepressant use should be monitored as SSRIs may induce apathy |
| Anosognosia | Decreased awareness of chorea and other symptoms; can cause disagreements with caregivers, especially regarding driving limitations |
Cognitive Decline
Progressive subcortical dementia with prominent frontal executive dysfunction (planning, set-shifting, judgment). Features include:
- Impaired Luria testing (executive dysfunction)
- Slowed processing speed
- Difficulty with complex tasks (managing finances, multitasking)
- Progressive language impairment
- Memory retrieval deficits (recognition better than recall, unlike cortical dementias)
Systemic Features
HD causes myriad systemic manifestations beyond the CNS: cardiac electrophysiologic abnormalities, sleep disruption, airway obstruction, dysphagia, sialorrhea, urinary and fecal incontinence, sexual dysfunction, and progressive weight loss with high caloric demands.
Neuroimaging
- Caudate atrophy: Progressive atrophy of the heads of the caudate nuclei is the most characteristic finding, detectable years before motor onset
- "Boxcar ventricles": Enlargement of the anterior horns of the lateral ventricles due to caudate atrophy — classic CT/MRI appearance
- Global cerebral atrophy: Progressive cortical and subcortical atrophy in advanced disease
- Volumetric MRI: Quantitative caudate and putamen volume measurements serve as HD-ISS Stage 1 biomarkers, detectable before clinical symptoms
Genetic Testing: The HDSA Protocol
HDSA Genetic Testing Recommendations
- Diagnostic testing (symptomatic patients): Confirm HD even with reported family history, as family history may be inaccurate and an accurate diagnosis avoids false negatives in predictive testing of family members
- Predictive testing (asymptomatic at-risk individuals): Follow the Huntington's Disease Society of America (HDSA) testing protocol, developed with at-risk individuals to ensure safe and supportive testing
- Pre-test counseling: Informed consent addressing emotional, family planning, and insurance implications
- Results in person: Always delivered face-to-face with psychosocial support
- Minor children: Should not undergo testing unless symptomatic (suspected juvenile-onset HD)
- Family planning: Some families use IVF with preimplantation genetic testing to avoid transmission
Critical: Studies demonstrate increased risk of suicidal ideation and suicide attempts following predictive testing. Genetic testing should be performed thoughtfully with appropriate psychological support infrastructure.
HD Integrated Staging System (HD-ISS)
Published by Tabrizi et al. in The Lancet Neurology (2022), the HD-ISS provides a standardized biological classification of HD using a genetic case definition (HTT CAG ≥40). It stages the disease from birth based on biological, clinical, and functional landmarks:
| Stage | Definition | Key Features |
|---|---|---|
| Stage 0 | Gene-positive, no detectable pathological change | HTT CAG ≥40 with no biomarker abnormalities. Individual has the mutation from birth but no measurable disease |
| Stage 1 | Biomarker changes without clinical symptoms | Measurable changes on quantitative neuroimaging (caudate/putamen volume loss) or cognitive biomarkers. No wet biomarker (e.g., NfL) has yet met the stringent criteria to serve as an HD-ISS landmark |
| Stage 2 | Prodromal HD | Subtle motor and/or cognitive signs on clinical assessment, but not sufficient for clinical diagnosis of HD |
| Stage 3 | Clinical HD | Overt motor, cognitive, and/or psychiatric symptoms meeting criteria for clinical diagnosis; encompasses all stages of functional decline |
The HD-ISS is transforming trial design by enabling enrollment of presymptomatic individuals (Stages 0–1) and providing standardized staging across studies.
HD Phenocopies
For patients with an HD-like phenotype (progressive chorea + cognitive decline + psychiatric changes + autosomal dominant inheritance) but negative HD genetic testing, phenocopies collectively account for approximately 5% of cases:
| Phenocopy | Inheritance | Key Distinguishing Features |
|---|---|---|
| C9orf72 disease | AD; hexanucleotide repeat | Most common phenocopy in White populations; can also cause FTD and ALS; upper motor neuron signs or weakness suggest this diagnosis; >60 repeats = fully penetrant |
| SCA17 (HDL4) | AD; CAG repeat in TBP | Second most common phenocopy; overlap of chorea and ataxia; White and Asian populations; MRI shows caudate and cerebellar atrophy; >42 repeats = penetrant |
| DRPLA | AD; CAG repeat in ATN1 | Very rare; predominantly Japanese (also Haw River syndrome in African Americans in North Carolina); seizures and myoclonus (especially childhood onset); WM changes + dentate/red nucleus/pallidal atrophy on MRI |
| HDL2 | AD; CTG/CAG in JPH3 | Most common phenocopy in sub-Saharan African descent; caudate atrophy on MRI; acanthocytes in 10%; >40 repeats = penetrant |
| HDL1 | AD; PRNP variation | Exceedingly rare; familial prion disease; prominent psychiatric features, seizures, myoclonus |
Other Genetic Causes of Adult-Onset Chorea
| Category | Disorders | Key Features / Tests |
|---|---|---|
| Basal ganglia mineralization | Neuroferritinopathy (AD, FTL), aceruloplasminemia (AR, CP), primary familial brain calcification / Fahr disease (AD, SLC20A2/XPR1) | Neuroferritinopathy: very low ferritin, prominent orobuccolingual chorea. Aceruloplasminemia: retinal degeneration, absent ceruloplasmin. Fahr: CT/MRI shows basal ganglia calcification |
| Neuroacanthocytosis | Chorea-acanthocytosis (AR, VPS13A), McLeod syndrome (X-linked, XK) | Generalized chorea with orobuccolingual predominance; tongue protrusion/feeding dystonia (chorea-acanthocytosis); acanthocytes on saline smear (false negatives common); elevated CK and liver enzymes; McLeod: reduced Kell antigen |
| Other | Wilson disease (AR, ATP7B), Niemann-Pick C (AR, NPC1/NPC2), Lubag (X-linked, TAF1) | Wilson disease: Treatable — never miss; low ceruloplasmin, elevated 24h urine copper, Kayser-Fleischer rings, MRI face-of-the-giant-panda sign. Test in all patients <50 years |
Nongenetic Causes of Chorea
| Category | Causes |
|---|---|
| Structural | Stroke, neoplasm, demyelinating disease |
| Infectious / parainfectious | Sydenham chorea (most common acute chorea in children), HIV encephalopathy, toxoplasmosis, cysticercosis, prion diseases, viral encephalitis |
| Autoimmune / paraneoplastic | SLE, antiphospholipid syndrome (chorea may be first presentation of SLE), NMDA receptor, IgLON5, dopamine-2 receptor, GABA receptor, neurexin-3α, GAD65 antibodies; anti-Hu, anti-Ma, VGCC, LGI1, CRMP-5, CASPR2 |
| Metabolic / endocrine | Hyperthyroidism, nonketotic hyperglycemia, electrolyte abnormalities, acquired hepatocerebral degeneration, uremia, vitamin deficiency (B12, B1) |
| Hematologic | Polycythemia vera, essential thrombocytopenia |
| Drug-induced | Levodopa/dopamine agonists, neuroleptics (tardive), antiepileptics (phenytoin, carbamazepine, lamotrigine, valproate, gabapentin), SSRIs, TCAs, stimulants, calcium channel blockers, oral contraceptives, steroids |
| Other | Post-cardiac arrest, carbon monoxide poisoning, post-pump chorea, chorea gravidarum, functional disorder |
Initial Chorea Workup in Adults
Systematic Evaluation
History (all patients): Disease acuity, age of onset, family history, medications, toxin exposure
Serum (all patients): CBC with smear, CMP, TSH, ESR, ANA, anticardiolipin antibodies, lupus anticoagulant, HIV, vitamin B12
Serum (select patients): Pregnancy test, ceruloplasmin (patients <50 years), autoimmune encephalitis panel (duration <1 year)
Imaging (all patients): Brain MRI (evaluate for structural lesions, atrophy patterns, iron/calcium deposition); head CT for calcification (Fahr disease)
Genetic testing: HD gene test for chronic progressive chorea; consider phenocopy genes if HD-negative; whole exome/genome if targeted testing non-diagnostic
Pediatric Chorea
Acute Onset
Sydenham chorea is the most common cause of acute chorea in children. It is a post-streptococcal autoimmune disorder (group A streptococcus antibodies targeting basal ganglia antigens). Diagnosis is clinical, supported by positive streptococcal culture and ASO/anti-DNase B antibodies (frequent false negatives with ASO). Can recur later in life with oral contraceptives or pregnancy (chorea gravidarum). Treat with penicillin. A 2024 meta-analysis supported antibiotics with corticosteroids and valproic acid.
Chronic / Genetic Onset
- Brain-lung-thyroid syndrome (benign hereditary chorea): Most common genetic chorea in children; NKX2-1 gene; minimal progression; associated pulmonary and thyroid manifestations can be severe; increased malignancy risk
- ADCY5-related dyskinesia: Early-onset facial myoclonus, axial hypotonia, episodic involuntary movements around sleep
- Juvenile-onset HD: ≥60 CAG repeats; predominantly parkinsonism, dystonia, and seizures rather than chorea
- Autosomal recessive ataxias: Ataxia-telangiectasia (ATM gene, elevated α-fetoprotein), Friedreich ataxia (rare chorea), ataxia with oculomotor apraxia types 1 and 2
- Metabolic disorders: Glutaric aciduria type 1, GLUT1 deficiency, Lesch-Nyhan syndrome, methylmalonic acidemia
Caregiver Considerations
Caregiver burden in HD is uniquely challenging: at-risk family caregivers may themselves be facing the possibility of developing HD, adding emotional weight to the physical toll of caregiving. Social stigma, functional decline, behavioral changes, and the progressive nature of the disease all contribute. Early involvement of social workers, genetic counselors, and psychologists is essential. Community education and awareness efforts help patients and families seek care with confidence.
Key References
- Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington's disease: the Integrated Staging System. Lancet Neurol. 2022;21(7):632–644.
- Stoker TB, Mason SL, Greenland JC, et al. Huntington's disease: diagnosis and management. Pract Neurol. 2022;22(1):32–41.
- Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis. Mov Disord. 2022;37(12):2327–2335.
- Shin C, Kim R, Yoo D, et al. A practical guide for clinical approach to patients with Huntington's disease. J Mov Disord. 2024;17(2):138–149.
- Kachian Z, Cohen-Zimerman S, Bega D, et al. Suicidal ideation and behavior in Huntington's disease: systematic review. J Affect Disord. 2019;250:319–329.
- Martinez-Ramirez D, Walker RH, Rodriguez-Violante M, Gatto EM. Review of hereditary and acquired rare choreas. Tremor Hyperkinetic Mov. 2020;10(1):24.
- Nance MA. Genetic testing protocol for Huntington's disease. Huntington's Disease Society of America.